Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009355 | 1.00 | CA1 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL3823617 | 1.00 | CA1 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL249566 | 1.00 | CA1 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL7637140 | 0.82 | CES2 (0.59) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL27860116 | 0.80 | CES2 (0.57) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL28855975 | 0.79 | CA1 (0.55) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL757101 | 0.79 | CES2 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL4949476 | 0.78 | CES2 (0.62) | CES2CES1PARP1KMT2AMEN1 | |
| SCHEMBL16321528 | 0.78 | CA1 (0.49) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL29733566 | 0.78 | CA1 (0.49) | CA1CA2CES2CES1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268640-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2016-10-12 | — | — | EP | claimed |
| US-8557991-B2 | Process for preparing enantiomerically pure indolopyridines | 4SC AG (DE) | 2013-10-15 | — | — | US | claimed |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2011-03-31 | — | — | US | claimed |
| EP-2268640-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009109620-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2009-09-11 | — | — | WO | claimed |
| EP-2098524-A1 | Process for preparing enantiomerically pure indolopyrinidines | 4SC AG (DE) | 2009-09-09 | — | — | EP | claimed |
| EP-1192134-B1 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1736469-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol | Aventis Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-6713627-B2 | FOR RECEPTOR ANTAGONISTS IN TREATMENT OF SCHIZOLPHRENIA, ANXIETY, VARIANT ANGINA, ANOREXIA VERVOSA, RAYNAUD'S PHENOMENON, INTERMITTENT CLAUDICATION, CORONARY OR PERIPHERAL VASOSPASMS, FIBROMYALGIA, CARDIAC ARRHYTHMIA'S, AND THROMBOSIS | AVENTIS PHARMACEUTICALS INC. | 2004-03-30 | — | — | US | claimed |
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTISUB II INC. | 2002-10-17 | — | — | US | claimed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | claimed |
| EP-4585601-A1 | NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE | Daiichi Sankyo Company, Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| CN-113382767-B | Urea compounds having substituents | 第一三共株式会社 | 2024-12-24 | — | — | CN | disclosed |
| CN-117222623-A | Acid addition salts of (S) -3- (2, 5-dimethoxy-4- (trifluoromethyl) phenyl) piperidine and (S) -3- (2-methoxy-5- (methylthio) -4- (trifluoromethyl) phenyl) piperidine, specific polymorphs thereof and processes for preparing the same | 罗弗拉有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | disclosed |
| WO-1998027085-A1 | NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998027086-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CBR1 | CA1 3834/4885CA2 4537/4885CES2 84/4885 |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | GRIK5, CYP3A5, GRK5 | CA1 2933/4885CA2 963/4885CES2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.